Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Patents
  • Published:

An export-only exception to pharmaceutical patents in Europe: should the United States follow suit?

Nature Biotechnology volume 37, pages 21–22 (2019)Cite this article

A new European Union policy could increase the supply of legitimate pharmaceuticals in developing countries and thereby minimize the problem of counterfeit medicines, but many challenges remain.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Max Planck Institute for Innovation and Competition. Study and annexes on the legal aspects of Supplementary Protection Certificates in the EU. https://ec.europa.eu/docsroom/documents/29524 (2018).

  2. Copenhagen Economics. Study of the economic impact of supplementary protection certificates, pharmaceutical incentives and rewards in Europe. https://ec.europa.eu/docsroom/documents/29521 (May 2018).

  3. European Commission. Proposal for a regulation of the European Parliament and of the Council amending Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products. COM/20182018/317 final – 2018/0161(COD). https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=COM:2018:317:FIN (2018).

  4. European Commission. Impact assessment accompanying the document “Proposal for a Regulation of the European Parliament and of the Council amending Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products.” https://ec.europa.eu/docsroom/documents/29463 (2018).

  5. EFPIA. EFPIA statement on the Commission's proposal to introduce an SPC manufacturing waiver, weakening Europe's knowledge based economy. https://www.efpia.eu/news-events/the-efpia-view/statements-press-releases/28052018-efpia-statement-on-the-commission-s-proposal-to-introduce-an-spc-manufacturing-waiver-weakening-europe-s-knowledge-based-economy/ (2018).

  6. Medicines for Europe. Risk that European Council will “neuter” SPC manufacturing waiver and give foreign (non-EU) manufacturers strong advantage over EU-based manufacturers. https://www.medicinesforeurope.com/news/risk-that-european-council-will-neuter-spc-manufacturing-waiver-and-give-foreign-non-eu-manufacturers-strong-advantage-over-eu-based-manufacturers/ (2018).

  7. Agreement on trade-related aspects of intellectual property rights (15 April 1994). Marrakesh Agreement Establishing the World Trade Organization, Annex 1C, 1869 U.N.T.S. 299, 33 I.L.M. 1197 (1994).

  8. Patent Law Amendments Act of 1984, Pub. L. No. 98–622 (1984) (codified at 35 U.S.C. § 271(f)).

  9. WesternGeco LLC v. ION Geophysical Corp., No. 16–1011, 138 S. Ct. 2129 (2018).

Download references

Acknowledgements

The authors gratefully acknowledge B. Bergsson for research support. This research was supported by a Novo Nordisk Foundation grant for a scientifically independent Collaborative Research Programme (grant number NNF17SA027784). J.J.D. and A.S.K. receive research support from the Laura and John Arnold Foundation, the Harvard Program in Therapeutic Science, and the Engelberg Foundation. The funders had no role in the conception, preparation, or approval of the manuscript, or in the decision to submit the manuscript for publication.

Author information

Authors and Affiliations

  1. Timo Minssen is at the Centre for Advanced Studies in Biomedical Innovation Law (CeBIL), University of Copenhagen, Denmark.,

    Timo Minssen

  2. Aaron S. Kesselheim and Jonathan J. Darrow are at Harvard Medical School and Brigham & Women's Hospital, Boston, Massachusetts, USA.,

    Aaron S Kesselheim & Jonathan J Darrow

Authors
  1. Timo Minssen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aaron S Kesselheim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jonathan J Darrow
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jonathan J Darrow.

Ethics declarations

Competing interests

T.M. is a member of the Expert Board for Copenhagen Economics' “Study on the economic impact of SPCs, pharmaceutical incentives and rewards in Europe” (European Commission (DG GROW), Tender reference number 590/PP/GRO/SME/16/F/121).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Minssen, T., Kesselheim, A. & Darrow, J. An export-only exception to pharmaceutical patents in Europe: should the United States follow suit?. Nat Biotechnol 37, 21–22 (2019). https://doi.org/10.1038/nbt.4324

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.4324

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing